said it's partner, Toronto-based Genpharm, received final approval from the U.S. Food and Drug Administration for a generic version of
Pravachol, a cholesterol drug.
The FDA approved pravastatin at 10 mg, 20 mg and 40 mg dosage levels. Par will begin shipping the product immediately.
Shares of Par were down 14 cents at $20.15.
This story was created through a joint venture between TheStreet.com and IRIS.